Company
MicroCures’ founder and chief scientific officer, David Sharp, Ph.D., is one of the world’s foremost experts on cell movement.
His pioneering research has helped highlight the key role that cell movement plays in all repair and regeneration within the human body. Based on this groundbreaking science, the company has established a first-of-its-kind therapeutic platform capable of precisely controlling the speed and direction of cell movement.
This novel scientific approach offers the potential to deliver powerful therapeutic benefits for a variety of large and underserved medical applications. Microcures has created a broad pipeline of therapeutic programs with an initial focus in the area of tissue, nerve and organ repair. Unlike regenerative medicine approaches that rely upon engineered materials or systemic growth factor/stem cell therapeutics, MicroCures’ technology directs and enhances the body’s inherent healing processes through local, temporary modulation of cell motility.
MicroCures is rapidly advancing its lead candidate, siFi2, for excisional wound healing, a multi-billion dollar market that is inadequately served with current treatment options. Multiple preclinical studies have demonstrated that the company’s technology produced statistically significant improvement and acceleration of wound repair.
Based on these findings, MicroCures expects to file an investigational new drug (IND) application in 2020 and initiate a Phase 1 clinical trial thereafter. The company’s pipeline also includes follow-on cell motility acceleration programs focused on burn healing, nerve regeneration and cardiac repair, as well as earlier-stage cell motility deceleration work designed to combat cancer metastases and fibrosis.
Proprietary technology to accelerate wound repair
MicroCures has developed a proprietary siRNA-based drug candidate, called siFi2, designed to silence the activity of FL2, thereby both accelerating the rate and improving the quality of wound repair.
Positioned as an industry leader
The company has built an extensive intellectual property estate offering protection for its underlying technology, as well as the therapeutic programs that have emerged from the platform. This comprehensive patent portfolio positions the company as the industry leader in therapeutic modulation of cell movement, while providing numerous partnering and licensing opportunities.